Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Mancini

Showing results (51-60 of 119) with videos related to

Pageof 12
Sort By:
Brain Sciences|October 27, 2022
Esports and Visual Attention: Evaluating In-Game Advertising through Eye-Tracking during the Game Viewing ExperienceMarco Mancini, Patrizia Cherubino, Giulia Cartocci, et al.
Annals of Hematology|June 7, 2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practiceEmilia Scalzulli, Matteo Molica, Danilo Alunni Fegatelli, et al.
Environmental Research|July 5, 2025
A gold nanoparticle-enhanced methylene blue electrochemical sensor for detecting waterborne anionic surfactants and PFASFederica Simonetti, Riccardo Buccini, Valentina Migliorati, et al.
Computational Intelligence and Neuroscience|May 31, 2019
Antismoking Campaigns' Perception and Gender Differences: A Comparison among EEG IndicesGiulia Cartocci, Enrica Modica, Dario Rossi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavirRobin Wood, Praphan Phanuphak, Pedro Cahn, et al.
Oncotarget|February 28, 2018
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinibMassimo Breccia, Matteo Molica, Gioia Colafigli, et al.
British Journal of Haematology|October 30, 2010
Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early interventionMassimo Breccia, Sonia M Orlandi, Roberto Latagliata, et al.
Hematological Oncology|May 8, 2015
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?Federico Vozella, Roberto Latagliata, Ida Carmosino, et al.
Brain Sciences|September 28, 2023
Time-Dependent Analysis of Human Neurophysiological Activities during an Ecological Olfactory ExperienceAlessia Vozzi, Ana Martinez Levy, Vincenzo Ronca, et al.
Blood|January 25, 2002
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problemRoberto Latagliata, Maria Concetta Petti, Susanna Fenu, et al.
Pageof 12

Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Brain Sciences|October 27, 2022
Esports and Visual Attention: Evaluating In-Game Advertising through Eye-Tracking during the Game Viewing ExperienceMarco Mancini, Patrizia Cherubino, Giulia Cartocci, et al.
Annals of Hematology|June 7, 2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practiceEmilia Scalzulli, Matteo Molica, Danilo Alunni Fegatelli, et al.
Environmental Research|July 5, 2025
A gold nanoparticle-enhanced methylene blue electrochemical sensor for detecting waterborne anionic surfactants and PFASFederica Simonetti, Riccardo Buccini, Valentina Migliorati, et al.
Computational Intelligence and Neuroscience|May 31, 2019
Antismoking Campaigns' Perception and Gender Differences: A Comparison among EEG IndicesGiulia Cartocci, Enrica Modica, Dario Rossi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavirRobin Wood, Praphan Phanuphak, Pedro Cahn, et al.
Oncotarget|February 28, 2018
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinibMassimo Breccia, Matteo Molica, Gioia Colafigli, et al.
British Journal of Haematology|October 30, 2010
Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early interventionMassimo Breccia, Sonia M Orlandi, Roberto Latagliata, et al.
Hematological Oncology|May 8, 2015
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?Federico Vozella, Roberto Latagliata, Ida Carmosino, et al.
Brain Sciences|September 28, 2023
Time-Dependent Analysis of Human Neurophysiological Activities during an Ecological Olfactory ExperienceAlessia Vozzi, Ana Martinez Levy, Vincenzo Ronca, et al.
Blood|January 25, 2002
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problemRoberto Latagliata, Maria Concetta Petti, Susanna Fenu, et al.
Pageof 12